The FDA's Gene-Therapy Reversal and the Exit of Vinay Prasad
WSJ Opinion: Potomac Watch
00:00
Intro
This chapter delves into the FDA's recent actions regarding a gene therapy for muscular dystrophy, focusing on a shipment halt that was reversed due to public outcry. It also examines the resignation of a key FDA figure and the broader challenges faced in the regulatory landscape for rare diseases.
Transcript
Play full episode
